4.7 Article

Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64

Journal

NATURE PROTOCOLS
Volume 1, Issue 6, Pages 3062-3068

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nprot.2006.431

Keywords

-

Funding

  1. NCI NIH HHS [R01 CA93375, R01 CA093375, F32 CA115148, R01 CA064475, R24 CA86307] Funding Source: Medline
  2. NATIONAL CANCER INSTITUTE [R24CA086307, F32CA115148, R01CA064475, R01CA093375] Funding Source: NIH RePORTER

Ask authors/readers for more resources

The number of radiopharmaceuticals containing copper radionuclides for diagnostic imaging and targeted radiotherapy has grown considerably over the past few decades. This expansion has created the need for protocols allowing for the efficient chelation of Cu-64 to peptide-chelator conjugates. Step 1A of this protocol describes a Cu-64-radiolabeling procedure for 1,4,8,11-tetraazacyclododecane-1,4,8,11-tetraacetic acid (TETA)-conjugated peptides. This reaction is facile and requires the incubation of (CuCl2)-Cu-64 in 0.1 M ammonium acetate buffer with the TETA-peptide for 30 min at room temperature (20-23 degrees C). Step 1B of this protocol describes the radiolabeling procedure for 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2] hexadecane (CB-TE2A)-conjugated peptides. The CB-TE2A-peptide can be labeled with Cu-64 in 0.1 M ammonium acetate buffer in 2 h at 95 degrees C. In both cases, the conjugates can be radiolabeled with 64Cu at greater than 95% purity and with specific activities of 37-111 MBq mu g(-1) (1-3 mCi mu g(-1)). Both protocols are straightforward and can be completed within 3 h.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available